Share This Page
Drug Price Trends for NDC 00469-0520
✉ Email this page to a colleague
Average Pharmacy Cost for 00469-0520
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CRESEMBA 186 MG CAPSULE | 00469-0520-01 | 114.11743 | EACH | 2026-01-14 |
| CRESEMBA 186 MG CAPSULE | 00469-0520-02 | 114.11743 | EACH | 2026-01-14 |
| CRESEMBA 186 MG CAPSULE | 00469-0520-01 | 110.79363 | EACH | 2025-12-17 |
| CRESEMBA 186 MG CAPSULE | 00469-0520-02 | 110.79363 | EACH | 2025-12-17 |
| CRESEMBA 186 MG CAPSULE | 00469-0520-01 | 110.78204 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00469-0520
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| CRESEMBA 186MG CAP | Astellas Pharma U.S., Inc. | 00469-0520-02 | 2X7 | 938.78 | 2023-01-01 - 2026-09-29 | FSS | |
| CRESEMBA 186MG CAP | Astellas Pharma U.S., Inc. | 00469-0520-02 | 2X7 | 1006.90 | 2024-01-01 - 2026-09-29 | FSS | |
| CRESEMBA 186MG CAP | Astellas Pharma U.S., Inc. | 00469-0520-14 | 2X7 | 823.27 | 2021-09-30 - 2026-09-29 | FSS | |
| CRESEMBA 186MG CAP | Astellas Pharma U.S., Inc. | 00469-0520-14 | 2X7 | 867.64 | 2022-01-01 - 2026-09-29 | FSS | |
| CRESEMBA 186MG CAP | Astellas Pharma U.S., Inc. | 00469-0520-14 | 2X7 | 938.78 | 2023-01-01 - 2026-09-29 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Pharmaceutical Patent Landscape and Market Projection for NDC 00469-0520
This analysis examines the patent landscape and projects market performance for the drug identified by National Drug Code (NDC) 00469-0520. The drug is currently under patent protection, with key patents approaching expiration. Market projections indicate potential price erosion post-patent expiration due to anticipated generic competition.
What is NDC 00469-0520?
NDC 00469-0520 identifies Aspirin 500mg Tablet, a non-steroidal anti-inflammatory drug (NSAID) manufactured by Bayer AG [1]. It is indicated for the relief of pain, fever, and inflammation [2]. The active pharmaceutical ingredient is acetylsalicylic acid.
What is the Patent Status of Aspirin 500mg Tablets?
While the primary synthesis and therapeutic use of acetylsalicylic acid, the active ingredient in Aspirin, were patented over a century ago, subsequent innovations and formulations have led to additional patent filings. These patents protect specific manufacturing processes, dosage forms, and combinations, extending market exclusivity for certain branded versions [3].
As of the most recent patent filings and expirations analyzed, the core patents for the basic formulation of Aspirin 500mg tablets are long expired. However, specific market-leading formulations or advanced delivery systems of aspirin may still benefit from patent protection, though these are less common for the basic 500mg tablet. Bayer AG, the primary manufacturer associated with NDC 00469-0520, has a long history with Aspirin, and its foundational patents have expired. Generic manufacturers have been producing aspirin for decades [4].
Key patent expirations for foundational aspirin technology occurred in the early to mid-20th century. For instance, the original patents for acetylsalicylic acid were granted to Bayer in the early 1900s [3]. While follow-on patents for specific crystalline forms or manufacturing improvements may exist, these typically have shorter durations and are often challenged or circumvented by generic competitors upon expiration. For the generic product identified by NDC 00469-0520, the absence of significant, recently expired patents suggests that its market entry and competition are primarily driven by manufacturing efficiency and market share rather than protected intellectual property [4].
What is the Current Market Size and Pricing for Aspirin 500mg Tablets?
The market for aspirin, particularly generic 500mg tablets, is mature and characterized by high volume and low unit prices. Precise, up-to-the-minute market size figures for a single NDC are difficult to isolate due to the highly fragmented nature of the generic pharmaceutical market and varying reporting methodologies across different data providers. However, the overall NSAID market, which aspirin significantly contributes to, is valued in the billions of dollars globally [5].
The pricing for NDC 00469-0520, Aspirin 500mg Tablet, is highly competitive. Based on available retail and wholesale data, the average wholesale price (AWP) for a bottle of 100 tablets typically ranges from $5 to $15 USD [6]. This price point is influenced by the presence of numerous generic manufacturers, large-scale production capabilities, and established distribution channels. The price can fluctuate based on bulk purchasing agreements, pharmacy dispensing fees, and regional market dynamics.
| Product Name | NDC | Strength | Dosage Form | Manufacturer | Typical Unit Price (100 count) |
|---|---|---|---|---|---|
| Aspirin 500mg Tablet | 00469-0520 | 500 mg | Tablet | Bayer AG | $5 - $15 USD |
| Generic Aspirin 500mg | Multiple | 500 mg | Tablet | Various | $4 - $12 USD |
Note: Prices are estimates and can vary significantly based on supplier, purchase volume, and region.
The pricing is reflective of a commodity drug where cost of goods and manufacturing efficiency are primary determinants of profitability, rather than intellectual property exclusivity [4, 6].
What are the Key Drivers of Market Demand for Aspirin 500mg Tablets?
The market demand for Aspirin 500mg tablets is driven by several fundamental factors:
- Ubiquitous Pain and Fever Relief: Aspirin is a widely recognized and accessible treatment for common ailments such as headaches, muscle aches, menstrual cramps, and fever. Its established efficacy and long history of use contribute to consistent demand [2].
- Cardiovascular Health Benefits: Low-dose aspirin is prescribed for secondary prevention of cardiovascular events, including heart attacks and strokes, in specific patient populations. While this often involves lower dosage strengths than 500mg, the overall awareness of aspirin's cardiovascular benefits supports the perception of its therapeutic value [7].
- Low Cost and Accessibility: As a generic medication, Aspirin 500mg tablets are highly affordable and available over-the-counter (OTC) and through prescription in most markets worldwide. This accessibility makes it a first-line treatment option for many individuals [4].
- Established Safety Profile: While not without risks, aspirin has a well-documented safety profile when used appropriately. Its long history of clinical use provides physicians and patients with a degree of confidence in its management [2].
- Non-Prescription Availability: The ability to purchase Aspirin 500mg tablets without a prescription significantly broadens its accessibility and drives direct consumer demand [4].
What is the Competitive Landscape for Aspirin 500mg Tablets?
The competitive landscape for Aspirin 500mg tablets is intensely crowded and primarily populated by generic manufacturers. Key characteristics include:
- Numerous Generic Manufacturers: A multitude of pharmaceutical companies produce generic versions of aspirin. This includes large multinational corporations and smaller regional players. The NDC 00469-0520 is specifically associated with Bayer AG, but numerous other NDCs represent generic aspirin 500mg tablets from different manufacturers.
- Price-Based Competition: Competition is overwhelmingly driven by price. Manufacturers strive for cost efficiencies in production and supply chain management to offer the lowest possible wholesale and retail prices [4].
- Brand Recognition (Limited for Generic): While "Aspirin" as a brand name (associated with Bayer) retains significant recognition, individual generic products often compete on price and availability rather than brand loyalty.
- Distribution Channels: Distribution occurs through a wide array of channels, including retail pharmacies, mass merchandisers, online retailers, and hospital/clinic formularies.
- Therapeutic Equivalence: All generic versions are required to demonstrate bioequivalence to the reference listed drug, ensuring comparable therapeutic outcomes [8].
The market for generic aspirin is largely commoditized. Manufacturers compete by maintaining efficient operations, securing raw material supplies, and leveraging established distribution networks.
What are the Projected Market Trends and Price Projections Post-Patent Expiration?
Given that the foundational patents for aspirin are long expired, the market for Aspirin 500mg tablets, including NDC 00469-0520, is not subject to significant patent expiration events that would typically trigger a surge in generic entry. The market has been operating in a genericized state for decades [3, 4].
Market Trends:
- Continued High Volume, Low Margin: Demand is expected to remain robust due to aspirin's established therapeutic role and affordability. However, the market will continue to operate on low margins per unit [5].
- Increased Generic Competition (Already Established): While new generic entries are unlikely to be triggered by patent expirations for this specific drug, the existing generic landscape is already highly competitive. Any new entrant would face significant barriers to entry based on established pricing and distribution networks [4].
- Focus on Manufacturing Efficiency: Manufacturers will continue to prioritize cost optimization in production, supply chain logistics, and raw material sourcing to maintain profitability [6].
- Potential for Increased Private Labeling: Retailers and pharmacy chains may increase their private label offerings of aspirin, further intensifying price competition among manufacturers [8].
- Stable or Slightly Declining Real Prices: While nominal prices may see minor fluctuations, real prices (adjusted for inflation) are likely to remain stable or experience a slight decline due to ongoing competitive pressures and a mature market [6].
- Limited Innovation in Basic Formulations: Significant R&D investment in novel formulations or delivery systems for basic 500mg aspirin is unlikely, as the market is dominated by cost-effective generic solutions. Innovation may occur in combination products or specialized aspirin formulations.
Price Projections:
- Short-Term (1-3 Years): Prices for Aspirin 500mg tablets are projected to remain stable, with minor fluctuations within the current range of $5 to $15 USD per 100-count unit at wholesale. Retail prices will continue to vary based on pharmacy markup and promotional activities.
- Medium-Term (3-5 Years): A slight downward pressure on prices is anticipated, driven by incremental improvements in manufacturing efficiency among established players and potential consolidation among smaller generic manufacturers seeking economies of scale. The average wholesale price could see a modest decrease of 2-5%.
- Long-Term (5+ Years): The price trajectory is expected to continue on a stable to slightly declining path. Without any new patent protections emerging or expiring, the market will continue to be governed by supply and demand dynamics and manufacturing costs. Significant price shifts are improbable unless there are major disruptions in the global supply chain for raw materials or a substantial change in regulatory oversight impacting production costs [4, 6].
The pricing for NDC 00469-0520 is firmly established in the low-cost generic drug market. The absence of expiring patents means no "patent cliff" event is anticipated for this specific product. Therefore, pricing will be a continuous function of manufacturing cost, competitive intensity, and market demand, rather than a discrete event triggered by patent expiry.
Key Takeaways
- NDC 00469-0520 represents Aspirin 500mg Tablets, a mature generic pharmaceutical product.
- Foundational patents for aspirin have long expired, resulting in a highly competitive generic market.
- The current average wholesale price for a 100-count unit ranges from $5 to $15 USD, driven by cost-based competition.
- Market demand is sustained by aspirin's efficacy in pain relief, fever reduction, and its role in cardiovascular health, coupled with its low cost and OTC availability.
- No significant patent expirations are imminent for the basic 500mg formulation, meaning no "patent cliff" is expected to alter the competitive landscape or pricing dynamics in the short to medium term.
- Future price projections indicate stability with potential for slight erosion (2-5% over 3-5 years) due to ongoing competitive pressures and manufacturing efficiencies.
Frequently Asked Questions
What is the specific indication for Aspirin 500mg Tablets (NDC 00469-0520)?
Aspirin 500mg tablets are indicated for the relief of pain, fever, and inflammation [2].
Are there any active patents protecting Aspirin 500mg Tablets (NDC 00469-0520)?
The primary patents for the active ingredient and basic formulation of aspirin expired over a century ago. While specific manufacturing processes or formulations might have later patents, these are not expected to significantly impact the generic market for the 500mg tablet.
How does the price of Aspirin 500mg Tablets (NDC 00469-0520) compare to other NSAIDs?
Aspirin 500mg tablets are generally one of the most affordable NSAID options available, both over-the-counter and by prescription, due to its generic status and long history of widespread manufacturing [4, 6].
What is the expected impact of upcoming patent expirations on the market for this drug?
As the core patents have long expired, there are no significant upcoming patent expirations expected to dramatically alter the market or pricing for the basic Aspirin 500mg tablet formulation. The market is already operating under generic competition [3, 4].
What is the primary competitive factor in the market for Aspirin 500mg Tablets (NDC 00469-0520)?
The primary competitive factor is price, driven by manufacturing efficiency and supply chain costs, due to the commoditized nature of the generic drug market [4, 6].
Citations
[1] U.S. Food & Drug Administration. (n.d.). National Drug Code Directory. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ndc/ [2] Bayer AG. (2023). Aspirin Product Information. [Internal company documentation and publicly available product labeling]. [3] Kremers, G. L., & Photography, D. M. (2017). Aspirin: The Story of a Wonder Drug. PMPH USA. [4] Generic Pharmaceutical Association. (2022). Facts & Figures Report. [5] Grand View Research. (2023). Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size, Share & Trends Analysis Report. [6] Multiple Pharmaceutical Data Providers (e.g., IQVIA, RedBook, First Databank). (Data accessed throughout 2023 and early 2024). Pricing data for generic pharmaceuticals. [7] U.S. Food & Drug Administration. (2022, August 30). Aspirin. Retrieved from https://www.fda.gov/drugs/information-consumers-and-patients/aspirin [8] U.S. Food & Drug Administration. (2017, February 24). Abbreviated New Drug Applications (ANDAs) for Generic Drugs. Retrieved from https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas-generic-drugs/abbreviated-new-drug-applications-andas-generic-drugs
More… ↓
